One signal

Novo, the company behind Ozempic, has struck a collaboration with Anthropic to speed up drug development. The Danish pharma giant, shortened from Novo Nordisk, will use Anthropic's models and Claude Science as it chases its goal of becoming the world's most AI-driven healthcare company.

Why it matters

The pitch is bold. Novo chief Mike Doustdar says the tie-up will 'supercharge' R&D into chronic disease treatments, while Dario Amodei argues frontier AI could 'compress a century's worth of biological and medical breakthroughs into a decade'. Politico reports the companies promise robust data governance and human oversight. The timing raises an eyebrow: Anthropic said last week that scientists had tried using Claude for bioweapons work, even as it sells into pharma. Watch for concrete proof that Claude shortens real drug pipelines.

Discuss: What evidence would convince you AI is genuinely compressing drug discovery timelines rather than powering R&D marketing?

Independent WittyWires Watcher; not an official account or feed.